124 related articles for article (PubMed ID: 11292463)
1. Behavioral sensitization to WIN55212.2 in rats pretreated with heroin.
Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
Brain Res; 2001 Apr; 898(1):178-80. PubMed ID: 11292463
[TBL] [Abstract][Full Text] [Related]
2. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat.
Pontieri FE; Monnazzi P; Scontrini A; Buttarelli FR; Patacchioli FR
Eur J Pharmacol; 2001 Jun; 421(3):R1-3. PubMed ID: 11516439
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Tanda G; Pontieri FE; Di Chiara G
Science; 1997 Jun; 276(5321):2048-50. PubMed ID: 9197269
[TBL] [Abstract][Full Text] [Related]
4. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.
Spano MS; Fattore L; Cossu G; Deiana S; Fadda P; Fratta W
Br J Pharmacol; 2004 Oct; 143(3):343-50. PubMed ID: 15339858
[TBL] [Abstract][Full Text] [Related]
5. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.
Niederhoffer N; Szabo B
Br J Pharmacol; 1999 Jan; 126(2):457-66. PubMed ID: 10077239
[TBL] [Abstract][Full Text] [Related]
6. Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats.
Pfitzer T; Niederhoffer N; Szabo B
Br J Pharmacol; 2004 Jul; 142(6):943-52. PubMed ID: 15226190
[TBL] [Abstract][Full Text] [Related]
7. Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: short-term regulation by intrinsic and extrinsic pathways.
Moranta D; Esteban S; García-Sevilla JA
J Neurosci Res; 2007 Feb; 85(3):656-67. PubMed ID: 17139682
[TBL] [Abstract][Full Text] [Related]
8. Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.
Gomez DM; Everett TJ; Hamilton LR; Ranganath A; Cheer JF; Oleson EB
Neuropharmacology; 2021 Jan; 182():108374. PubMed ID: 33115642
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.
Solinas M; Panlilio LV; Tanda G; Makriyannis A; Matthews SA; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2046-57. PubMed ID: 15870833
[TBL] [Abstract][Full Text] [Related]
10. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding.
Freedland CS; Poston JS; Porrino LJ
Pharmacol Biochem Behav; 2000 Oct; 67(2):265-70. PubMed ID: 11124390
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study.
Wu WC; Wang Y; Chai CY
Chin J Physiol; 2008 Jun; 51(3):152-9. PubMed ID: 18935910
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits.
Niederhoffer N; Szabo B
J Pharmacol Exp Ther; 2000 Aug; 294(2):707-13. PubMed ID: 10900251
[TBL] [Abstract][Full Text] [Related]
13. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2.
Song ZH; Slowey CA
J Pharmacol Exp Ther; 2000 Jan; 292(1):136-9. PubMed ID: 10604940
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats.
Fattore L; Spano MS; Cossu G; Deiana S; Fratta W
Eur J Neurosci; 2003 Apr; 17(8):1723-6. PubMed ID: 12752390
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
Rinaldi-Carmona M; Barth F; Héaulme M; Alonso R; Shire D; Congy C; Soubrié P; Brelière JC; Le Fur G
Life Sci; 1995; 56(23-24):1941-7. PubMed ID: 7776817
[TBL] [Abstract][Full Text] [Related]
17. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
18. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
20. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
